Latest news with #MSK-related
Yahoo
4 days ago
- Business
- Yahoo
Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees
ROSEMONT, Ill., May 29, 2025 /PRNewswire/ -- The Orthopaedic Research and Education Foundation (OREF), the leading private nonprofit organization funding musculoskeletal (MSK) research across all orthopaedic sub-specialties, is pleased to announce that Ivan Tornos, Chairman, President and CEO of orthopaedic medical device company Zimmer Biomet has joined its Board of Trustees. Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics. Prior to his appointment as President and Chief Executive Officer in 2023, he held the positions of Group President, Global Businesses and the Americas, and Chief Operating Officer with responsibility for overseeing all global businesses at Zimmer Biomet. He was elected Chairman of the Board of Directors of Zimmer Biomet, a global leader in musculoskeletal health, in May of 2025. OREF Board President, Joshua J. Jacobs, MD, stated, "On behalf of the entire board, I am delighted to welcome Ivan to OREF. Our two organizations have a long history of collaboration and a shared commitment to improving patient care and outcomes. Ivan's presence on the OREF board will bring heightened visibility to our mission and to the need for more research funding. His service to OREF and the financial support of Zimmer Biomet underscore his commitment to improving the health of our communities here in the U.S. and throughout the world." "I am thrilled to be joining the OREF board. Now more than ever, it's important we move with a sense of urgency and deep purpose to ensure that musculoskeletal research advances at a much faster pace and delivers even bolder solutions. There are countless patients currently waiting on the sidelines who could benefit from the meaningful work that we will do together, and I'm committed to doing all I can to reduce the current gaps in this area," said Ivan Tornos. The growing burden of MSK conditions in the United States is well documented with MSK-related diseases and injuries affecting more than half of the adult population and imposing an estimated economic burden of $980 billion annually.1 Despite the outsized impact of MSK diseases on quality of life and the U.S. economy, funding for MSK conditions is disproportionately low when comparing the physical and economic burden of various diseases. OREF is a leading voice in advocating for increased MSK research funding and strongly believes that the nation's healthcare will not improve unless and until MSK research funding becomes a national priority. OREF grantees' success in securing additional funding from the NIH and other government entities is unparalleled within the MSK research community. Research published in JBJS demonstrates that OREF grant recipients are more likely to receive subsequent NIH funding compared to other applicants (23.5 percent vs. 20.6 percent), with Career Development Grant recipients achieving a 48.4 percent success rate.2 Given the limited availability of MSK research funds, investing in a reputable independent source with a proven return on investment is essential. OREF's collaboration with more than 60 MSK-related organizations is a key factor in its success in funding significant and impactful research that improves clinical practice and patient outcomes. About OREF An independent 501(c)3 nonprofit, OREF strives to improve clinical care and patient outcomes by advancing innovative research, developing new investigators, and uniting the orthopaedic community in promoting musculoskeletal health. The Foundation raises funds to support research on diseases and injuries of bones, nerves, muscles, and tendons and to enhance clinical care leading to improved health, increased activity, and a better quality of life for patients. For more information, visit or follow OREF on X and LinkedIn. 1United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States (BMUS), Third Edition, 2014. Rosemont, IL. Available at 2Li, Alan K. BS1,a; Kendal, Joseph K. MD, MSc2; Hamad, Christopher D. MD2; Peterson, Nicholas V. MD2; Asachi, Parsa BA1; Taylor, Jeremiah M. BS1; Le, Michael M. MD1; Lloyd, Trevor S. BS1; Wessel, Lauren E. MD2; Bernthal, Nicholas M. MD2. Identifying Predictors of Successful Conversion from OREF Grants to Extramural Federal Funding Among Orthopaedic Surgeons. The Journal of Bone and Joint Surgery 107(1):p 96-103, January 1, 2025. DOI: 10.2106/JBJS.24.0064 View original content to download multimedia: SOURCE Orthopaedic Research and Education Foundation
Yahoo
08-04-2025
- Business
- Yahoo
Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion
Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition management NEW YORK, April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions. The signed agreement is already live and generating recurring revenue in 2025, marking a significant milestone in Dario's ongoing expansion among innovation-driven employers seeking measurable health outcomes and ROI. The institution's decision to implement Dario's full suite of solutions reinforces the Company's momentum in the enterprise healthcare segment and contributes to its position as a trusted provider of clinically proven, scalable digital health solutions. Chosen for its proven impact, personalization, and seamless integration, Dario's AI-driven platform will provide employees with data-driven support through its full suite of solutions—Dario Health, Dario Mind, and Dario Move—spanning multiple chronic conditions, including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. "In today's competitive benefits landscape, employers are demanding solutions that deliver real-world results — not just promises," said Steven Nelson, Chief Commercial Officer of DarioHealth. "We believe this partnership sends a strong signal that leading organizations are moving beyond generic wellness apps and toward data-driven platforms that scale quickly and demonstrate clinical, financial, and cultural ROI. Dario is proving that we're not only easy to deploy, but powerful enough to meet the performance standards of the most demanding enterprise workforces in the country." The newly added employer is a nationally strategic institution with a central role in U.S. healthcare and technology initiatives. Their decision to adopt Dario reflects a commitment to offering employees a personalized health journey supported by AI, real-time data, and integrated coaching—all delivered through a single, user-friendly platform. Dario's momentum in the employer space continues to build, with engagement rates well above industry averages and early outcomes showing significant reductions in A1c, blood pressure, and MSK-related pain—alongside measurable improvements in mental well-being. The agreement provides further market validation of Dario's approach as a scalable, clinically integrated solution. As digital health adoption accelerates, Dario believes that partnerships with leading healthcare systems will be a key marker of trust and reliability in the sector. About DarioHealth Corp. DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit Cautionary Note Regarding Forward-Looking Statements This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expectation that the agreement will generate recurring revenue in 2025, its belief that Dario's AI-driven platform will provide employees with data-driven support through its full suite of solutions, the forecast that leading organizations are moving beyond generic wellness apps and toward data-driven platforms, its belief that the Dario platform is powerful enough to meet the performance standards of the most demanding enterprise workforces in the country, that Dario's momentum in the employer space continues to build, and its belief that partnerships with leading healthcare systems will be a key marker of trust and reliability in the sector. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. DarioHealth Corporate Contact: Mary MooneyVP Marketingmary@ +1-312-593-4280 DarioHealth Investor Relations Contact: Kat ParrellaInvestor Relations Manager kat@ +315-378-6922 Logo: View original content: SOURCE DarioHealth Corp. Sign in to access your portfolio
